We should suspect this mutation in patients younger than 50 years old, with postlingual bilateral sensorineural hearing loss that is more pronounced at high frequency.
Prevalence of the A1555G MTDNA mutation in sporadic hearing-impaired patients without known history of aminoglycoside treatment
 
  Keywords
 
 
  
   Aminoglycosides
  
 
 
  
   Mitochondrial DNA
  
 
 
  
   Sensorineural hearing loss
  
 
Abstract
 Introduction
The A1555G mitochondrial DNA (mtDNA) mutation is responsible for <dis>maternally inherited non-syndromic hearing loss</dis> that is increased by aminoglycoside exposure.
The objective of this study was to ascertain the frequency of the A1555G mutation among patients without family history of <dis>hearing loss</dis> or known exposition to aminoglycosides.
Methods
We screened for the mtDNA A1555G mutation in Spanish patients with <dis>sporadic sensorineural hearing impairment</dis> without a known family history of <dis>hearing loss</dis> or aminoglycoside exposition seen at the ENT Department in Sierrallana Hospital (Torrelavega, Cantabria, Spain) over a four-year period.
Results
A total of 219 patients with <dis>bilateral hearing loss</dis> were screened.
Two of them (0.9%) had the A1555G mitochondrial DNA mutation.
Both patients had a <dis>moderate bilateral sensorineural hearing loss for low frequency</dis>, and moderate to severe loss for high-frequency.
Conclusions
The mtDNA A1555G mutation in patients with <dis>sensorineural hearing loss</dis> without family history of <dis>deafness</dis> or aminoglycoside ototoxicity is infrequent in our region.
We should suspect this mutation in patients younger than 50 years old, with <dis>postlingual bilateral sensorineural hearing loss</dis> that is more pronounced at high frequency.
Abstract
 Introduction
The A1555G mitochondrial DNA (mtDNA) mutation is responsible for maternally inherited non-syndromic hearing loss that is increased by aminoglycoside exposure.
The objective of this study was to ascertain the frequency of the A1555G mutation among patients without family history of hearing loss or known exposition to aminoglycosides.
Methods
We screened for the mtDNA A1555G mutation in Spanish patients with sporadic sensorineural hearing impairment without a known family history of hearing loss or aminoglycoside exposition seen at the ENT Department in Sierrallana Hospital (Torrelavega, Cantabria, Spain) over a four-year period.
Results
A total of 219 patients with bilateral hearing loss were screened.
Two of them (0.9%) had the A1555G mitochondrial DNA mutation.
Both patients had a moderate bilateral sensorineural hearing loss for low frequency, and moderate to severe loss for high-frequency.
Conclusions
The mtDNA A1555G mutation in patients with sensorineural hearing loss without family history of deafness or aminoglycoside ototoxicity is infrequent in our region.
We should suspect this mutation in patients younger than 50 years old, with postlingual bilateral sensorineural hearing loss that is more pronounced at high frequency.
We should suspect this mutation in patients younger than 50 years old, with <dis>postlingual bilateral sensorineural hearing loss</dis> that is more pronounced at high frequency.
postlingual bilateral sensorineural hearing loss
DISABILITY